Pharma Business Structure, M&As Evolving To Create Smaller Cross-Functional Units
This article was originally published in PharmAsia News
TOKYO - Strategies for mergers and acquisitions in the global pharmaceutical market are changing from marriages of equals to alliances and buyouts with biotechs, which often create cross-functional smaller units within big pharmas, said Hiroshi Nakamura, professor at the Keio University Business School
You may also be interested in...
Takeda is the latest big pharma paying its way into Alnylam's not-so-exclusive club, with the firm having agreed to pay Alnylam $150 million upfront in exchange for worldwide, non-exclusive access to its RNA interference therapeutics platform technology in two therapeutic areas: oncology and metabolic disease
Looking to increase global market share, Pfizer has established a business unit devoted to oncology within its worldwide pharmaceutical group, in part, to strengthen research investment on cancers common in Asia, including liver, esophagus and nasopharynx
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).